| Aviva Menuha Hopkovitz, MD | |
|
8200 Walnut Hill Lane, Dallas, TX 75231-4402 | |
| (214) 345-7280 | |
| (214) 345-4487 |
| Full Name | Aviva Menuha Hopkovitz |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 37 Years |
| Location | 8200 Walnut Hill Lane, Dallas, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265493126 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZC0500X | Pathology - Cytopathology | H4420 (Texas) | Secondary |
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | H4420 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Texas Health Presbyterian Hospital Dallas | Dallas, TX | Hospital |
| Texas Health Presbyterian Hospital Denton | Denton, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Dallas Pathology Services Pa | 6002890480 | 10 |
News Archive
The Nova Scotia Department of Health and Wellness has approved the listing of LITHMAX (Lithium Carbonate Sustained-Release 300mg Tablets) in the Nova Scotia Formulary, effective April 19th, 2011. This announcement comes as welcome news to patients in need of the sustained-release formulation of Lithium Carbonate who require help to pay for prescribed medications.
New international guidelines published in the journal Transplantation reinforce the use of a new type of blood test to assess cytomegalovirus (CMV) risk in solid organ transplant recipients (i.e. transplant recipients). This blood test, QuantiFERON®-CMV (QF-CMV), is the first commercially-available blood test to allow physicians to monitor a person's risk of CMV disease. Most commonly used in the transplant setting, QF-CMV may predict which transplant recipients are at increased risk of CMV disease after transplant surgery.
Increased levels of a protein that helps regulate the body's blood pressure may also predict a major cardiovascular event in high-risk patients, according to a study led by St. Michael's Hospital's cardiovascular surgeon Subodh Verma. Measuring the amount of the protein, known as plasma renin activity (PRA), in the blood stream may give doctors another tool to assess a patient's risk and help prevent a heart attack or stroke.
A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.
BioScrip, Inc. today announced 2012 first quarter financial results. First quarter revenue was $155.6 million and net loss was $2.7 million, or $0.05 per share. Consolidated Adjusted EBITDA for the first quarter was $8.4 million.
› Verified 9 days ago
| Entity Name | North Dallas Pathology Services Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548221625 PECOS PAC ID: 6002890480 Enrollment ID: O20040614001699 |
News Archive
The Nova Scotia Department of Health and Wellness has approved the listing of LITHMAX (Lithium Carbonate Sustained-Release 300mg Tablets) in the Nova Scotia Formulary, effective April 19th, 2011. This announcement comes as welcome news to patients in need of the sustained-release formulation of Lithium Carbonate who require help to pay for prescribed medications.
New international guidelines published in the journal Transplantation reinforce the use of a new type of blood test to assess cytomegalovirus (CMV) risk in solid organ transplant recipients (i.e. transplant recipients). This blood test, QuantiFERON®-CMV (QF-CMV), is the first commercially-available blood test to allow physicians to monitor a person's risk of CMV disease. Most commonly used in the transplant setting, QF-CMV may predict which transplant recipients are at increased risk of CMV disease after transplant surgery.
Increased levels of a protein that helps regulate the body's blood pressure may also predict a major cardiovascular event in high-risk patients, according to a study led by St. Michael's Hospital's cardiovascular surgeon Subodh Verma. Measuring the amount of the protein, known as plasma renin activity (PRA), in the blood stream may give doctors another tool to assess a patient's risk and help prevent a heart attack or stroke.
A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.
BioScrip, Inc. today announced 2012 first quarter financial results. First quarter revenue was $155.6 million and net loss was $2.7 million, or $0.05 per share. Consolidated Adjusted EBITDA for the first quarter was $8.4 million.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Aviva Menuha Hopkovitz, MD Po Box 744127, Dallas, TX 75374-4127 Ph: (214) 345-7280 | Aviva Menuha Hopkovitz, MD 8200 Walnut Hill Lane, Dallas, TX 75231-4402 Ph: (214) 345-7280 |
News Archive
The Nova Scotia Department of Health and Wellness has approved the listing of LITHMAX (Lithium Carbonate Sustained-Release 300mg Tablets) in the Nova Scotia Formulary, effective April 19th, 2011. This announcement comes as welcome news to patients in need of the sustained-release formulation of Lithium Carbonate who require help to pay for prescribed medications.
New international guidelines published in the journal Transplantation reinforce the use of a new type of blood test to assess cytomegalovirus (CMV) risk in solid organ transplant recipients (i.e. transplant recipients). This blood test, QuantiFERON®-CMV (QF-CMV), is the first commercially-available blood test to allow physicians to monitor a person's risk of CMV disease. Most commonly used in the transplant setting, QF-CMV may predict which transplant recipients are at increased risk of CMV disease after transplant surgery.
Increased levels of a protein that helps regulate the body's blood pressure may also predict a major cardiovascular event in high-risk patients, according to a study led by St. Michael's Hospital's cardiovascular surgeon Subodh Verma. Measuring the amount of the protein, known as plasma renin activity (PRA), in the blood stream may give doctors another tool to assess a patient's risk and help prevent a heart attack or stroke.
A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.
BioScrip, Inc. today announced 2012 first quarter financial results. First quarter revenue was $155.6 million and net loss was $2.7 million, or $0.05 per share. Consolidated Adjusted EBITDA for the first quarter was $8.4 million.
› Verified 9 days ago
Dr. Jaime Albert Campbell, M.D., M.S. Pathology Medicare: Accepting Medicare Assignments Practice Location: 3500 Gaston Ave, Baylor University Medical Center, Dept Of Pathology, Dallas, TX 75246 Phone: 214-820-3772 | |
Brianne Flynn, Pathology Medicare: Not Enrolled in Medicare Practice Location: 2355 N Stemmons Fwy, Dallas, TX 75207 Phone: 214-920-5900 | |
Dr. Timothy Joseph Kirtek, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd Stop 7200, Dallas, TX 75390 Phone: 214-648-3433 | |
Keith Allen Wharton Jr., MD PHD Pathology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-1620 Fax: 214-648-4080 | |
Dinesh Rakheja, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-648-1620 Fax: 214-648-4080 | |
Dr. Emmy L. Kiss, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 5323 Harry Hines Blvd, Dallas, TX 75390 Phone: 214-590-6494 | |
Thomas Hugh Mcconnell, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 3401 Lee Pkwy Apt 304, Dallas, TX 75219 Phone: 214-363-2221 Fax: 214-363-2228 |